OFIX · Orthofix Medical Inc. · Stock research

Current Thesis

The leg on offer in July was a reimbursement-reversal re-rate, and it has now been given back in full. CMS restored the pre-2026-05-18 Medicare rates on non-invasive bone growth stimulators (HCPCS E0747/E0748/E0760), reported 2026-07-02; the 2026-08-05 Q2 print then cleared consensus on both lines and carried an FY26 guidance raise to $845–855M of net sales and $95–98M of adjusted EBITDA. The tape treated the confirming event as an exit. Seeking Alpha put the print-day reaction near -10% (2026-08-06), the shares closed $10.28 on 2026-08-07 and $10.01 on 2026-08-21 — 38.3% below the $16.23 52-week high, with RSI(14) at 22.8. A three-month price change of -6.9% puts the last close under the level of 2026-05-21, the day the guidance-cut 8-K landed. What the reversal was supposed to pay for has been unwound, and the next dated company event is the Q3 print in early November.

Bullish and bearish views on Orthofix Medical Inc.

The model's bull view on Orthofix Medical Inc. (OFIX), in brief: CMS restoration is in force rather than pending: pre-May-18 rates restored per the company statement reported 2026-07-02, reversing the ~10% average cut the 2026-05-21 8-K identified as the reason guidance was pulled down. The bear view: Both post-print sell-side actions landed on the same number: Stifel cut to $13 from $15 with Buy maintained (~2026-08-06) and Canaccord Genuity cut to $13 with Buy maintained (2026-08-10). Both cases follow in full.

Bull Case

• CMS restoration is in force rather than pending: pre-May-18 rates restored per the company statement reported 2026-07-02, reversing the ~10% average cut the 2026-05-21 8-K identified as the reason guidance was pulled down.
• FY26 guidance moved up on both lines on 2026-08-05 — net sales to $845–855M from $838–848M, adjusted EBITDA to $95–98M from $90–93M, framed by the company as roughly 80bps of margin expansion versus 2025.
• Q2 2026 beat: net sales $210.933M against a $209.277M consensus, adjusted EPS $0.07 against a $(0.41) estimate, reported sales +4% YoY and ~5% pro forma constant currency.
• Concentration is working where the revenue actually sits: at Canaccord Genuity's 46th Annual Growth Conference on 2026-08-12, management said ~80% of spine revenue comes from the top 40 distributors and that cohort is growing above market.
• CFO Julie Andrews gave the first quantified Q3 shape since the print on 2026-08-12 — Q3 revenue expected roughly level with Q2, and "a little bit of expansion versus prior year EBITDA margin."
• Multi-year cash trajectory cited at that conference: free cash flow improved from a $108M outflow in 2023 to near breakeven in 2025 (Investing.com conference coverage, 2026-08-12).

Bear Case

• Both post-print sell-side actions landed on the same number: Stifel cut to $13 from $15 with Buy maintained (~2026-08-06) and Canaccord Genuity cut to $13 with Buy maintained (2026-08-10). The 5-analyst average of $21.50 (range $16–$24) displayed on stockanalysis.com as of 2026-08-08 is being marked down toward the tape.
• Profitability moved backwards on higher sales: Q2 2026 net loss $(15.8)M versus $(14.1)M a year earlier; adjusted EBITDA $20.1M versus $20.6M.
• Six-month free cash flow $(47.1)M against $(20.6)M in the prior-year period. The 2026-05-21 8-K said the company does not expect positive free cash flow for full-year 2026. Quarter-end cash and equivalents $103.8M against $221.6M of long-term debt. A ~$15M European MDR inventory purchase pushes cash out in 2026 with receipts expected in 2027 (2026-08-12).
• The smaller-distributor drag was quantified, not resolved: the ~20% of spine revenue outside the top 40 has declined for several quarters and more steeply than management expected (2026-08-12), and the company is selectively deciding which of those partners to keep.
• No 2027 guidance and no reinstated long-range plan until the U.S. spine business stabilises (2026-08-12). The three-year targets withdrawn on 2026-05-21 stayed withdrawn through a raised FY26 guide.
• FDA's 2026-04-16 reclassification of non-invasive bone growth stimulators from Class III to Class II lowers the 510(k) barrier into the Therapeutic Solutions franchise, which did $64.2M in Q2 at +2.5%.

Setup & Price Structure

The narrative is dead. The narrative got its policy confirmation on 2026-07-02 and its fundamental confirmation on 2026-08-05, and price is lower after both — $10.01 on 2026-08-21 versus $10.28 on 2026-08-07, with a three-month change of -6.9% that places the shares beneath the 2026-05-21 guidance-cut day. A story whose two designed catalysts both fired and left the stock at a lower level has stopped attracting the marginal buyer it needed.

Positioning and crowding observables, stated as observables:

• RSI(14) at 22.8 on 2026-08-21 — deep oversold. Such readings persist inside downtrends and are not by themselves evidence of a base.
• Sell-side targets converging downward within five sessions (Stifel $13 on ~2026-08-06, Canaccord $13 on 2026-08-10) while both kept Buy ratings — targets compressing toward price with ratings unchanged.
• Retail-facing coverage clustered in early July (Benzinga's 2026-07-06 gainer list grouped OFIX with WULF, IREN, CRDO and others) and has gone quiet since; the last 30 days of headlines carry one analyst action and no company release.
• Insider flow: Form 4 coverage shows director John B. no open-market insider purchase has been reported at the lower August levels through 2026-08-21.
• No earnings date inside the next 30 days, so there is no scheduled event to force repositioning.

Structure: the $10 handle is the operative reference, intact by a cent-scale margin at the 2026-08-21 close. Below it, the July advance is fully round-tripped with no dated company event until roughly 2026-11-04. Evidence of stabilisation would be weekly closes that stop making lower lows and a reclaim of the 2026-08-07 close of $10.28; that has not occurred in the two weeks between those two closes.

Catalyst Calendar (next 30 days)

• 2026-08-22 → 2026-09-21: no company-dated event. The last announced appearances were Needham's Virtual MedTech & Diagnostics 1x1 Conference (2026-08-10) and Canaccord Genuity's 46th Annual Growth Conference (2026-08-12); no September conference had been announced as of 2026-08-22.
• ~2026-10-01 (est.) — CMS quarterly DMEPOS fee-schedule update effective date, with the file posting ahead of it. Tests whether the restored E0747/E0748/E0760 rates carry forward unchanged.
• ~2026-11-04 (est.) — Q3 2026 results; Q3 2025 was reported 2025-11-04. First full quarter under restored reimbursement.
• ~2027-02-25 (est.) — Q4/FY2026 results and any FY2027 guide; FY2025 results were released 2026-02-24.

What Would Change Our Mind

The stabilisation case is entirely dependent on the Q3 print supplying three things at once: adjusted EBITDA above the year-ago $20.6M, free cash flow inflecting off the $(47.1)M six-month figure, and revenue landing at or above Q2's $210.9M as the CFO indicated on 2026-08-12. A reinstated long-range plan or an early FY2027 range would signal management's own confidence in the reimbursement base has returned; their continued absence on 2026-11-04 keeps the guide unsupported by anything beyond a single quarter.

On the tape, a weekly close below $9.80 loses the $10 handle held at the 2026-08-21 close, completing the retrace of the entire July CMS-reversal advance. In the other direction, weekly closes reclaiming the 2026-08-07 level of $10.28 while holding the $10 handle would be the first structural evidence that the distribution since 2026-08-05 is finished.

Structural negatives that would settle the question: a downward revision to HCPCS E0747/E0748/E0760 in a quarterly DMEPOS update, a competitor 510(k) clearance for a non-invasive bone growth stimulator, or any equity/convertible issuance or credit-facility amendment filed against the $221.6M long-term debt.

Correlation Notes

• Reimbursement beta dominates: the two largest moves of 2026 (2026-05-21 cut, 2026-07-02 restoration) were CMS-driven and independent of operating results. Other DMEPOS-exposed device names share that factor.
• U.S. spine peers (Globus Medical, Alphatec and the SeaSpine-lineage names) share the distributor-productivity and hospital-pricing cycle management described on 2026-08-12, including the 1–2% annual price erosion built into projections.
• Small-cap medtech liquidity: the 2026-07-06 Benzinga list grouped OFIX with unrelated small caps on a single risk-appetite day, which is how the name trades in the absence of company news.
• FX: the gap between +4% reported and ~5% pro forma constant-currency Q2 growth, plus the euro-denominated MDR inventory build, makes EUR/USD a second-order input to reported revenue and 2026 cash outflow.